Skip to main content
NCBI home page
Experimental & Molecular Medicine logoLink to Experimental & Molecular Medicine
. 2008 Jun 20;40(3):313–319. doi: 10.3858/emm.2008.40.3.313

Effect of xanthohumol on melanogenesis in B16 melanoma cells

Jeung-Hyun Koo 1,*, Hyoung Tae Kim 4,*, Ha-Yong Yoon 1, Kang-Beom Kwon 2, Il-Whan Choi 3, Sung Hoo Jung 5, Han-Uk Kim 6, Byung-Hyun Park 1, Jin-Woo Park 1,✉
PMCID: PMC2679287  PMID: 18587269

Abstract

Xanthohumol (XH), the principal prenylflavonoid of the hop plant (Humulus lupulus L.), dose-dependently inhibited isobutylmethylxanthine (IBMX)-induced melanogenesis in B16 melanoma cells, with little cytotoxicity at the effective concentrations. Decreased melanin content was accompanied by reduced tyrosinase enzyme activity, protein and mRNA expression. The levels of tyrosinase-related protein 1 and 2 mRNAs were decreased by XH. XH also inhibited α-melanocyte stimulating hormone- or forskolin-induced increases in melanogenesis, suggesting an action on the cAMP-dependent melanogenic pathway. XH downregulated the protein and mRNA expression of microphthalmia-associated transcription factor (MITF), a master transcriptional regulator of key melanogenic enzymes. These results suggest that XH might act as a hypo-pigmenting agent through the downregulation of MITF in the cAMP-dependent melanogenic pathway.

Keywords: cell differentiation, melanins, melanocytes, microphthalmia-associated transcription factor, monophenol monooxygenase, xanthohumol

Introduction

Melanin is a unique pigmented biopolymer synthesized by melanocytes, dendritic cells that exist in the dermal-epidermal border of the skin. Melanin has a number of important functions, including the determination of phenotypic appearance, protective coloration, balance and auditory processing, absorption of toxic drugs and chemicals, and neurologic development during embryogenesis (Hearing, 1998). Melanogenesis itself is a complex process, with at least 125 distinct genes involved in the regulation of melanogenesis either directly or indirectly (Yamaguchi et al., 2007). Mutations of these genes are associated with different pigmentary diseases, including various forms of ocular and oculocutaneous albinism, piebaldism, Hirschsprung's disease, and Waardenberg's syndrome (Hearing, 1999).

The tyrosinase gene family plays an pivotal role in the regulation of melanogenesis (Pawelek and Chakraborty, 1998). The tyrosinase gene family consists of tyrosinase, tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2) (Hearing, 1999). Tyrosinase is a bifunctional enzyme that modulates melanin production, first by catalyzing the hydroxylation of tyrosine to DOPA and secondly by catalyzing the oxidation of DOPA to DOPAquinone (Hearing and Jimenez, 1987). TRP-2, which functions as a DOPAchrome tautomerase, catalyzes the rearrangement of DOPAchrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) (Yokoyama et al., 1994), and TRP-1 oxidizes DHICA to a carboxylated indole-quinone (Kobayashi et al., 1994). Microphthalmia-associated transcription factor (MITF) is a master regulator of melanocyte development and melanogenesis (Levy et al., 2006). It is a melanocyte-specific transcription factor, and regulates the transcription of three major pigmentation enzymes: tyrosinase, TRP-1, and TRP-2. The promoters of these genes contain the MITF consensus E-box sequence and are expressed in melanocytes.

Understanding the mechanisms of melanogenesis is of great interest pharmaceutically and cosmeceutically. Inhibitors of melanin synthesis are related to localized hyper-pigmentation in humans, such as melasma, lentigines, nevus, ephelis, and post-inflammatory state. In human epidermis, α-melanocyte stimulating hormone (α-MSH) and adrenocorticotropic hormone are produced and released by keratinocytes after UV radiation, and are involved in the regulation of melanogenesis and/or melanocyte dendrite formation (Wakamatsu et al., 1997). α-MSH and adrenocorticotropic hormone bind to a melanocyte-specific receptor, MC1-R (Cone et al., 1996), which activates adenylate cyclase through G proteins to elevate intracellular cAMP (Costin and Hearing, 2007). Cyclic AMP increases the expression of melanogenic enzymes in part through PKA (Busca and Ballotti, 2000). UV radiation also affects melanogenesis through the activation of the diacylglycerol/PKC pathway, nitric oxide/cGMP pathway, or the SOS responses to UV-induced DNA damage (Costin and Hearing, 2007).

Flavonoids are constituents of food and drinks that include flavones (7,8-benzoflavone), flavonols (quercetin), flavanol (cathechin), flavanones (naringenin), isoflavones (genistein), and chalcones (xanthohumol). Xanthohumol (XH) has been isolated from hop "cones," the female inflorescences of the hop plant (Humulus lupulus L.) that are largely used in the brewing industry as a preservative and flavoring agent to add bitterness and aroma to beer. Chemically, XH belongs to the prenylated chalcones (open C-ring flavonoids) class, and is the main prenylflavonoid of hops (0.1-1% on dry weight) (Stevens and Page, 2004). XH is an antioxidant (Miranda et al., 2000) and a broad-spectrum cancer chemopreventive agent that prevents carcinogenesis in the initiation, promotion, and progression phase (Gerhauser et al., 2002; Pan et al., 2005; Plazar et al., 2007). It also inhibits adipogenesis (Yang et al., 2007) and osteoporosis (Tobe et al., 1997), and potentially influences AIDS (Wang et al., 2004) and malaria (Frolich et al., 2005), at least in vitro. However, to our knowledge, there is no report about the effect of XH on melanogenesis. In this study, we observed that XH can effectively inhibit isobutylmethylxanthine (IBMX)- induced melanogenesis in B16 melanoma cells.

Materials and Methods

Cells and Materials

The B16/F10 murine melanoma cell line was obtained from the Korean Cell Line Bank (Seoul, Korea). Cells were cultured in DMEM containing 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.25 µg/ml amphotericin B at 37℃ in a humidified 95% air/5% co2 atmosphere as described previously (Jung et al., 2001). XH was obtained from Alexis Biochemicals (Lausen, Switzerland), and α-MSH, IBMX, and forskolin were obtained from Sigma (St. Louis, MO). Drug treatment began 24 h after seeding, and cells were harvested after 2 days of incubation.

Melanin content measurement

The melanin content of the cultured B16 cells were measured as described previously (Yang et al., 2006). The cells were washed twice with PBS and lysed with 20 mM Tris-0.1% Triton X-100 (pH 7.5). Cell lysates were precipitated with the same amount of 20% trichloroacetic acid. After washing twice with 10% trichloroacetic acid, the pellets were treated with ethyl alcohol:diethyl ether (3 : 1) and diethyl ether successively. Samples were air-dried, dissolved in 1 ml of 0.85 M KOH, and boiled for 15 min. After cooling, absorbance was measured with a spectrophotometer at 440 nm. The amount of cellular melanin was corrected according to the protein content of the samples. The protein content was determined by the method of Bradford (Bradford, 1976).

Tyrosinase activity assay

Tyrosinase activity was assayed as DOPA oxidase activity (Lerch, 1987) with some modifications as described previously (Lv et al., 2007). Cell lysate was obtained after washing twice with PBS. Tyrosinase activity was analyzed spectrophotometrically by following the oxidation of DOPA to DOPAchrome at 475 nm. The reaction mixture containing 100 µl of freshly prepared substrate solution (0.1% L-DOPA in 0.1 M sodium phosphate, pH 6.0) and 50 µl of enzyme solution was incubated at 37℃. The absorbance change was measured during the first 10 min of the reaction while the increase of the absorbance was linear, and corrections for auto-oxidation of L-DOPA in controls were made. The tyrosinase activity was corrected according to the protein content of the samples and presented as % of IBMX-treated control cells.

MTT assay

Viability of cultured cells was determined by reduction of MTT (Sigma) to formazan (Mosmann, 1983). Cells were seeded in 96-well plates and cultured for 24 h. After drug treatment, MTT (5 mg/ml in PBS, 100 µl) was added to each well. Cells were incubated at 37℃ for 30 min and DMSO (100 µl) was added to dissolve the formazan crystals. The absorbance was measured at 570 nm with a spectrophotometer (Spectra Max Plus, Molecular Devices, Sunnyvale, CA).

Western blot analysis

Cells were homogenized in ice-cold lysis buffer. The homogenates containing 10 µg of protein were separated by SDS-PAGE with a 10% resolving and 3% acrylamide stacking gel (Laemmli, 1970), and transferred to a nitrocellulose membrane (Millipore, Billerica, MA) in a Western blot apparatus (Bio-Rad, Hercules, CA) run at 100 V for 1.5 h. The nitrocellulose membrane was blocked with 2% BSA (Sigma), and then incubated overnight with 1 µg/ml goat anti-murine tyrosinase IgG (sc-7834, Santa-Cruz, CA), goat anti-human MITF IgG (sc-10999, Santa-Cruz) or monoclonal anti-actin IgG (A5441, Sigma). The binding of antibody was detected with anti-goat or anti-murine IgG conjugated with HRP (Sigma). Immunoblots were developed using an Enhanced Chemiluminescence Plus kit (Amersham Biosciences, Buckinghamshire, UK), and the intensity of the bands was measured by an LAS-1000 (Fujifilm, Tokyo, Japan).

RT-PCR

Total cellular RNA was prepared using Trizol solution (Invitrogen, Praisley, UK) according to the manufacturer's instructions. After the preparation of cDNA with oligo d(T)16 as a reverse transcriptase primer from the extracted RNA, amplification with PCR was performed using GeneAmp kit (Perkin EImer, Foster City, CA) according to the manufacturer's manual. The oligonucleotide primers used for PCR are as follows: tyrosinase upstream 5'-GGCCAGCTTTCAGGCAGAGGT-3'; downstream 5'-TGGTGCTTCATGGGCAAAATC-3': TRP-1 upstream 5'-GCTGCAGGAGCCTTCTTTCTC-3'; downstream 5'-AAGACGCTGCACTGCTGGTCT-3': TRP-2 upstream 5'-GGATGACCGTGAGCAATGGCC-3'; downstream 5'-CGGTTGTGACCAATGGGTGCC-3': MITF upstream 5'-GTATGAACACGCACTCTCTCGA-3'; downstream 5'-CTTCTGCGCTCATACTGCTC-3'; β-actin upstream 5'-ACCGTGAAAAGATGACCCAG-3'; downstream 5'-TACGGATGTCAACGTCACAC-3'. cDNA amplification used the product of about 1 µg of the total RNA. The reaction was cycled 28 times (for tyrosinase), 25 times (for TRP-1 and -2) and 35 times (for MITF) for 60 s at 94℃, 60 s at 56℃ and 60 s at 72℃. Fifty percent of the reaction mixture was analyzed by electrophoresis on 1% agarose gels and stained by ethidium bromide. The intensity of the bands was measured by LAS-1000 (Fujifilm, Tokyo, Japan).

Statistical analysis

Statistical analysis of the data was performed using ANOVA and Duncan's test. Differences with P < 0.05 were considered statistically significant.

Results

When B16 cells were incubated with IBMX, an inhibitor of phosphodiesterase (Beavo et al., 1970), the cell suspension turned black, indicating increased cellular melanogenesis (Figure 1A). XH dose-dependently decreased this IBMX-induced black color (Figure 1A), with significant inhibition observed from 0.5 µM XH (Figure 1B). No cytotoxicity was observed until 2.5 µM of XH as determined by the MTT assay. Even at 5 µM XH, 73.0% ± 4.6% of cells were still viable, while the cellular melanin content was decreased to 6.51% ± 1.13% of IBMX-treated cells.

Figure 1.

Figure 1

Open in a new tab

Effect of XH on melanin content and cytotoxicity in B16 melanoma cells. Cells (5 × 106 cells/well) were incubated with various concentrations of XH in the presence of 0.1 mM IBMX for 2 days. Melanin and protein content were determined as described in "Materials and Methods". Cell viability was determined by MTT assay. Data are expressed as a percentage of IBMX-treated control and presented as mean ± SEM of three separate experiments. *P < 0.05 and **P < 0.01 vs. IBMX-treated control.

XH dose-dependently decreased cellular tyrosinase activity (Figure 2), the rate-limiting step in melanin biosynthesis, in parallel with the decreased melanin content (Figure 1). However, in vitro preincubation of enzyme with XH for 30 min at 4℃ did not affect the tyrosinase activity. At 20 µM concentration of XH, the remaining activity was 95.4 ± 5.9% of control, indicating that the decrease in cellular tyrosinase activity by XH was not due to the direct inhibition of enzyme activity.

Figure 2.

Figure 2

Open in a new tab

Effect of various concentrations of XH on cellular tyrosinase activity. Cells (5 × 106 cells) were treated with various concentrations of XH in the presence of 0.1 mM IBMX for 2 days. Tyrosinase activity in cellular lysates was determined as described in "Materials and Methods". Data are expressed as a percentage of IBMX-treated controls and presented as mean ± SEM of three separate experiments. *P < 0.05 and **P < 0.01 vs. IBMX-treated control.

IBMX treatment increased tyrosinase protein expression, and this induction could be dose-dependently inhibited by XH (Figure 3). XH also decreased tyrosinase mRNA levels (Figure 4). These results indicate that XH inhibited tyrosinase at the transcriptional level. XH decreased the mRNA expression of TRP-1 and TRP-2, members of the tyrosinase gene family, as well (Figure 4).

Figure 3.

Figure 3

Open in a new tab

Effect of XH on tyrosinase and MITF protein expression. Cells (5 × 106 cells) were treated with a range of concentrations (0.5-10 µM) of XH in the presence or absence of 0.1 mM IBMX for 2 days. Tyrosinase and MITF protein was analyzed by Western blotting as described in "Materials and Methods". Experiments were performed three times with similar results and typical one is presented. Lane 1, control; lane 2, 0.1 mM IBMX; lane 3-5, 0.1 mM IBMX with 0.5 µM (lane 3), 5 µM (lane 4) and 10 µM (lane 5) XH.

Figure 4.

Figure 4

Open in a new tab

Effect of XH on mRNA expression of melanogenesis-related genes. (A) Cells (5 × 106 cells) were treated with 0.1 mM IBMX for 2 days in the presence or absence of 5 µM XH. Then cells were harvested and total RNA was extracted. mRNA expression was visualized by RT-PCR and quantitated as described in "Materials and Methods". The sizes of amplified gene products were 528 bp for β-actin, 477 bp for tyrosinase, 268 bp for TRP-1, 1044 bp for TRP-2, and 910 bp for MITF. Data are expressed as a percentage of IBMX-treated cells and presented as the mean ± SEM of three separate experiments. *P < 0.05 and **P < 0.01 vs IBMX-treated control.

Cellular melanin content was significantly increased in cells treated with 5 µM α-MSH or 5 µM forskolin (Figure 5). α-MSH produced by keratinocytes increases adenylate cyclase activity of melanocytes through G proteins (Busca and Ballotti, 2000), and forskolin is a direct activator of adenylate cyclase (Tamagawa et al., 1985). XH significantly inhibited the melanogenesis induced by both α-MSH and forskolin (Figure 5), suggesting that XH regulates the expression of the tyrosinase gene family through a cAMP-dependent pathway.

Figure 5.

Figure 5

Open in a new tab

Effect of XH on α-MSH-, IBMX- and forskolin-induced melanogenesis. (A) Cells (5 × 106) were incubated with 5 µM XH in the presence of IBMX (0.1 mM), α-MSH (5 µM), or forskolin (5 µM) for 2 days. Melanin and protein content were determined as described in "Materials and Methods". Data are expressed as a percentage of IBMX-treated control and presented as mean ± SEM of three separate experiments. **P < 0.01 vs. each drug control.

cAMP-mediated activation of PKA induces the expression of MITF, a master transcriptional regulator for melanogenic enzymes (Levy et al., 2006), and tyrosinase family proteins are important targets of MITF. The presence of XH significantly decreased the expression of MITF mRNA (Figure 4) and protein (Figure 3) expression, suggesting that XH worked by down-regulating MITF transcription.

Discussion

Here, IBMX-treated B16 melanoma cells were used to investigate the effect of XH on melanogenesis. Exposure of skin to UV radiation is the most common environmental stimuli for skin pigmentation. UV-induced hyperpigmentation occurs in two stages, an immediate darkening and a delayed tanning reaction. Immediate pigment darkening results from oxidation of pre-existing melanin and redistribution of melanosomes. In contrast, the delayed tanning response is photoprotective against subsequent UV injury, begins as the immediate pigmentation reaction fades, and progresses for at least 3-5 days after UV exposure (Eller and Gilchrest, 2000). Delayed tanning is preceded by increased tyrosinase activity in melanocytes (Eller and Gilchrest, 2000; Costin and Hearing, 2007). In B16 cells treated with IBMX, increased melanogenesis was associated with increased tyrosinase activity, protein and mRNA expression, which are similar with delayed tanning response after UV irradiation.

The melanocyte-keratinocyte complex of the skin responds quickly to a wide range of environmental stimuli, often in paracrine and/or autocrine manners. IBMX increases cellular cAMP through the inhibition of the cAMP-degrading enzyme, phosphodiesterase (Beavo et al., 1970). XH blocked IBMX-induced increases in melanogenesis at the transcriptional level of tyrosinase, suggesting an action on the cAMP-dependent pathway. α-MSH (Wakamatsu et al., 1997), a peptide acting on the MC1-R of melanocytes (Cone et al., 1996; Wakamatsu et al., 1997), and forskolin, an activator of adenylate cyclase (Tamagawa et al., 1985), both increased cellular melanin content in B16 cells. XH significantly inhibited the melanogenesis induced by both of these factors, supporting the idea that XH works on a cAMP-dependent pathway.

PKA phosphorylates and activates the cAMP response element binding protein that binds to the cAMP response element in the M promoter of the MITF gene (Tachibana, 2000; Levy et al., 2006). MITF is a tissue restricted, basic helix-loop-helix leucine zipper (b-HLH-Zip), dimeric transcription factor, and its mutation leads to defects in melanocytes, the retinal pigmented epithelium, mast cells, and osteoclasts in mice (Levy et al., 2006). In humans, mutations affecting the MITF pathway lead to pigmentary and auditory defects that are known collectively as Waardenburg syndrome (Lin and Fisher, 2007). The increase in MITF-M expression induces the up-regulation of tyrosinase gene family, which leads to increased melanin synthesis (Busca and Ballotti, 2000; Levy et al., 2006). XH significantly decreased the expression of MITF mRNA, suggesting that XH inhibits MITF transcription. Suppression of MITF mRNA was followed by decreased expression of tyrosinase and TRP-1 and -2 mRNAs.

In addition to the cAMP/PKA pathway, melanogenesis requires the cross-talking of several signaling pathways including diacylglycerol/PKC, nitric oxide/protein kinase G (PKG), tyrosine kinase pathway, or the SOS response to UV- induced DNA damage (Costin and Hearing, 2007). PKC-induced activation of tyrosinase occurs through phosphorylation rather than the synthesis of new enzyme (Park et al., 1993). However, PKG can increase the expression of tyrosinase protein (Sasaki et al., 2000). Alteration of melanocyte ERK activity by various paracrine cytokines can affect the MITF degradation (Xu et al., 2000; Kim et al., 2006). Induction of p53 increases the expression of hepatocyte nuclear factor-1α, which directly increases the transcription of MITF and tyrosinase (Schallreuter et al., 2003; Schallreuter, 2007). The additional effects of XH on other pathways and their cross-talking require further study.

In addition to the roles of protecting skin from harmful solar UV radiation or toxic chemicals, melanin determines racial and phenotypic appearance. The accumulation of melanin in specific parts of the skin as more pigmented patches such as melasma, freckles, ephelides, or senile lentigines might become an aesthetic problem (Solano et al., 2006). Elucidating the molecular mechanisms underlying hyperpigmentation could lead to technology that allows unwanted pigmentation to be decreased and photoaging to be preserved, as well as the design of tanning products with the potential to reduce the risk of skin cancer. Recently, natural herbal extracts and compounds have gained attention as putative hypo-pigmenting agents (Parvez et al., 2006; Solano et al., 2006). In this study, we showed that XH could inhibit IBMX-induced melanogenesis by inhibiting tyrosinase and related enzyme expression via down-regulating MITF expression, a key regulatory transcription factor of melanogenesis. Safety after long-term application is important, and no toxicity was observed after oral administration of XH (5 × 10-4 M) at libitum for 4 weeks in laboratory mice (Vanhoecke et al., 2005). Lifelong treatment of XH at a daily dose of 100 mg/kg body weight in a two-generation study did not affect the development of rats (Hussong et al., 2005). These results suggest that XH may be a safe hypo-pigmenting agent.

Acknowledgement

This work was supported by the Regional Research Centers Program of the Korean Ministry of Education and Human Resources Development through the Center for Healthcare Technology Development, a grant from the Basic Research Program of the Korea Science and Engineering Foundation (R01-2005-000-11028-0), and the Chonbuk National University (to I. W. Choi).

Abbreviations

DHICA

5,6-dihydroxyindole-2-carboxylic acid

IBMX

isobutylmethylxanthine

MITF

microphthalmia-associated transcription factor

PKG

protein kinase G

TRP

tyrosinase-related protein

XH

xanthohumol

α-MSH

α-melanocyte stimulating hormone

References

  • 1.Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW, Newman EV. Effects of xanthine derivatives on lipolysis and on adenosine 3',5'-monophosphate phosphodiesterase activity. Mol Pharmacol. 1970;6:597–603. [PubMed] [Google Scholar]
  • 2.Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  • 3.Busca R, Ballotti R. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res. 2000;13:60–69. doi: 10.1034/j.1600-0749.2000.130203.x. [DOI] [PubMed] [Google Scholar]
  • 4.Cone RD, Lu D, Koppula S, Vage DI, Klungland H, Boston B, Chen W, Orth DN, Pouton C, Kesterson RA. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res. 1996;51:287–317. [PubMed] [Google Scholar]
  • 5.Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. Faseb J. 2007;21:976–994. doi: 10.1096/fj.06-6649rev. [DOI] [PubMed] [Google Scholar]
  • 6.Eller MS, Gilchrest BA. Tanning as part of the eukaryotic SOS response. Pigment Cell Res. 2000;13(Suppl 8):94–97. doi: 10.1034/j.1600-0749.13.s8.17.x. [DOI] [PubMed] [Google Scholar]
  • 7.Frolich S, Schubert C, Bienzle U, Jenett-Siems K. In vitro antiplasmodial activity of prenylated chalcone derivatives of hops (Humulus lupulus) and their interaction with haemin. J Antimicrob Chemother. 2005;55:883–887. doi: 10.1093/jac/dki099. [DOI] [PubMed] [Google Scholar]
  • 8.Gerhauser C, Alt A, Heiss E, Gamal-Eldeen A, Klimo K, Knauft J, Neumann I, Scherf HR, Frank N, Bartsch H, Becker H. Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Mol Cancer Ther. 2002;1:959–969. [PubMed] [Google Scholar]
  • 9.Hearing VJ, Jimenez M. Mammalian tyrosinase--the critical regulatory control point in melanocyte pigmentation. Int J Biochem. 1987;19:1141–1147. doi: 10.1016/0020-711x(87)90095-4. [DOI] [PubMed] [Google Scholar]
  • 10.Hearing VJ. Regulation of melanin formation. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP, editors. The Pigmentary System: Physiology and Pathophysiology. New York, NY: Oxford University Press, Inc; 1998. pp. 423–438. [Google Scholar]
  • 11.Hearing VJ. Biochemical control of melanogenesis and melanosomal organization. J Investig Dermatol Symp Proc. 1999;4:24–28. doi: 10.1038/sj.jidsp.5640176. [DOI] [PubMed] [Google Scholar]
  • 12.Hussong R, Frank N, Knauft J, Ittrich C, Owen R, Becker H, Gerhauser C. A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats. Mol Nutr Food Res. 2005;49:861–867. doi: 10.1002/mnfr.200500089. [DOI] [PubMed] [Google Scholar]
  • 13.Jung GD, Yang JY, Song ES, Park JW. Stimulation of melanogenesis by glycyrrhizin in B16 melanoma cells. Exp Mol Med. 2001;33:131–135. doi: 10.1038/emm.2001.23. [DOI] [PubMed] [Google Scholar]
  • 14.Kim DS, Park SH, Kwon SB, Park ES, Huh CH, Youn SW, Park KC. Sphingosylphosphorylcholine-induced ERK activation inhibits melanin synthesis in human melanocytes. Pigment Cell Res. 2006;19:146–153. doi: 10.1111/j.1600-0749.2005.00287.x. [DOI] [PubMed] [Google Scholar]
  • 15.Kobayashi T, Urabe K, Winder A, Jimenez-Cervantes C, Imokawa G, Brewington T, Solano F, Garcia-Borron JC, Hearing VJ. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. Embo J. 1994;13:5818–5825. doi: 10.1002/j.1460-2075.1994.tb06925.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  • 17.Lerch K. Monophenol monooxygenase from Neurospora crassa. Methods Enzymol. 1987;142:165–169. doi: 10.1016/s0076-6879(87)42025-9. [DOI] [PubMed] [Google Scholar]
  • 18.Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12:406–414. doi: 10.1016/j.molmed.2006.07.008. [DOI] [PubMed] [Google Scholar]
  • 19.Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature. 2007;445:843–850. doi: 10.1038/nature05660. [DOI] [PubMed] [Google Scholar]
  • 20.Lv N, Koo JH, Yoon HY, Yu J, Kim KA, Choi IW, Kwon KB, Kwon KS, Kim HU, Park JW, Park BH. Effect of Angelica gigas extract on melanogenesis in B16 melanoma cells. Int J Mol Med. 2007;20:763–767. [PubMed] [Google Scholar]
  • 21.Miranda CL, Stevens JF, Ivanov V, McCall M, Frei B, Deinzer ML, Buhler DR. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J Agric Food Chem. 2000;48:3876–3884. doi: 10.1021/jf0002995. [DOI] [PubMed] [Google Scholar]
  • 22.Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  • 23.Pan L, Becker H, Gerhauser C. Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptor- and mitochondrial pathway. Mol Nutr Food Res. 2005;49:837–843. doi: 10.1002/mnfr.200500065. [DOI] [PubMed] [Google Scholar]
  • 24.Park HY, Russakovsky V, Ohno S, Gilchrest BA. The β isoform of protein kinase C stimulates human melanogenesis by activating tyrosinase in pigment cells. J Biol Chem. 1993;268:11742–11749. [PubMed] [Google Scholar]
  • 25.Parvez S, Kang M, Chung HS, Cho C, Hong MC, Shin MK, Bae H. Survey and mechanism of skin depigmenting and lightening agents. Phytother Res. 2006;20:921–934. doi: 10.1002/ptr.1954. [DOI] [PubMed] [Google Scholar]
  • 26.Pawelek JM, Chakraborty AK. The enzymology of melanogenesis. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne J-P, editors. The Pigmentary System: Physiology and PathoPhysiology. New York, NY: Oxford University Press, Inc; 1998. pp. 391–400. [Google Scholar]
  • 27.Plazar J, Zegura B, Lah TT, Filipic M. Protective effects of xanthohumol against the genotoxicity of benzo(a)pyrene (BaP), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and tert-butyl hydroperoxide (t-BOOH) in HepG2 human hepatoma cells. Mutat Res. 2007;632:1–8. doi: 10.1016/j.mrgentox.2007.03.013. [DOI] [PubMed] [Google Scholar]
  • 28.Sasaki M, Horikoshi T, Uchiwa H, Miyachi Y. Up-regulation of tyrosinase gene by nitric oxide in human melanocytes. Pigment Cell Res. 2000;13:248–252. doi: 10.1034/j.1600-0749.2000.130406.x. [DOI] [PubMed] [Google Scholar]
  • 29.Schallreuter KU, Kothari S, Hasse S, Kauser S, Lindsey NJ, Gibbons NC, Hibberts N, Wood JM. In situ and in vitro evidence for DCoH/HNF-1α transcription of tyrosinase in human skin melanocytes. Biochem Biophys Res Commun. 2003;301:610–616. doi: 10.1016/s0006-291x(02)03076-0. [DOI] [PubMed] [Google Scholar]
  • 30.Schallreuter KU. Advances in melanocyte basic science research. Dermatol Clin. 2007;25:283–291. doi: 10.1016/j.det.2007.04.010. [DOI] [PubMed] [Google Scholar]
  • 31.Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006;19:550–571. doi: 10.1111/j.1600-0749.2006.00334.x. [DOI] [PubMed] [Google Scholar]
  • 32.Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. 2004;65:1317–1330. doi: 10.1016/j.phytochem.2004.04.025. [DOI] [PubMed] [Google Scholar]
  • 33.Tachibana M. MITF: a stream flowing for pigment cells. Pigment Cell Res. 2000;13:230–240. doi: 10.1034/j.1600-0749.2000.130404.x. [DOI] [PubMed] [Google Scholar]
  • 34.Tamagawa T, Niki H, Niki A. Insulin release independent of a rise in cytosolic free Ca2+ by forskolin and phorbol ester. FEBS Lett. 1985;183:430–432. doi: 10.1016/0014-5793(85)80825-5. [DOI] [PubMed] [Google Scholar]
  • 35.Tobe H, Muraki Y, Kitamura K, Komiyama O, Sato Y, Sugioka T, Maruyama HB, Matsuda E, Nagai M. Bone resorption inhibitors from hop extract. Biosci Biotechnol Biochem. 1997;61:158–159. doi: 10.1271/bbb.61.158. [DOI] [PubMed] [Google Scholar]
  • 36.Vanhoecke BW, Delporte F, Van Braeckel E, Heyerick A, Depypere HT, Nuytinck M, De Keukeleire D, Bracke ME. A safety study of oral tangeretin and xanthohumol administration to laboratory mice. In Vivo. 2005;19:103–107. [PubMed] [Google Scholar]
  • 37.Wakamatsu K, Graham A, Cook D, Thody AJ. Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res. 1997;10:288–297. doi: 10.1111/j.1600-0749.1997.tb00688.x. [DOI] [PubMed] [Google Scholar]
  • 38.Wang Q, Ding ZH, Liu JK, Zheng YT. Xanthohumol, a novel anti-HIV-1 agent purified from Hops Humulus lupulus. Antiviral Res. 2004;64:189–194. doi: 10.1016/j.antiviral.2004.08.005. [DOI] [PubMed] [Google Scholar]
  • 39.Xu W, Gong L, Haddad MM, Bischof O, Campisi J, Yeh ET, Medrano EE. Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9. Exp Cell Res. 2000;255:135–143. doi: 10.1006/excr.2000.4803. [DOI] [PubMed] [Google Scholar]
  • 40.Yamaguchi Y, Brenner M, Hearing VJ. The regulation of skin pigmentation. J Biol Chem. 2007;282:27557–27561. doi: 10.1074/jbc.R700026200. [DOI] [PubMed] [Google Scholar]
  • 41.Yang JY, Koo JH, Song YG, Kwon KB, Lee JH, Sohn HS, Park BH, Jhee EC, Park JW. Stimulation of melanogenesis by scoparone in B16 melanoma cells. Acta Pharmacol Sin. 2006;27:1467–1473. doi: 10.1111/j.1745-7254.2006.00435.x. [DOI] [PubMed] [Google Scholar]
  • 42.Yang JY, Della-Fera MA, Rayalam S, Baile CA. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis. 2007;12:1953–1963. doi: 10.1007/s10495-007-0130-4. [DOI] [PubMed] [Google Scholar]
  • 43.Yokoyama K, Yasumoto K, Suzuki H, Shibahara S. Cloning of the human DOPAchrome tautomerase/tyrosinase-related protein 2 gene and identification of two regulatory regions required for its pigment cell-specific expression. J Biol Chem. 1994;269:27080–27087. [PubMed] [Google Scholar]

Articles from Experimental & Molecular Medicine are provided here courtesy of Korean Society for Biochemistry and Molecular Biology

RESOURCES